Clinical Translation

A systematic review in Frontiers in Digital Health screened 12,423 records and analyzed 177 studies of brain-computer interfaces in elderly care, identifying six recurring ethical themes: privacy and data security, informed consent and autonomy, personhood and identity, technical risk and safety, equity and access, and risk-benefit trade-offs. The authors argue those risks are built into the technology's interaction logic rather than sitting at its margins: decoding uncertainty can turn into care misjudgment, the inferability of neural data extends privacy exposure into psychological territory and power asymmetry, and technology-mediated communication strains trust and accountability. Responsible deployment, they conclude, requires embedding ethical principles systematically into care processes.

An August 2026 Neurotech Reports analysis cites Neuralink’s June 2025 $650 million Series E when examining uneven funding. Author Sharena Rice argues that large rounds do not imply broadly easier financing for startups, and considers platform funding alongside treatment-network expansion. Her assessment of tighter funding paths is an interpretation; specific award totals for the next NIH Blueprint MedTech cycle were not public.

NeuroXess announced that its self-developed implantable brain-computer interface system for hand motor function compensation — the 'fully implanted, fully wireless, fully functional' ('Sanquan') system — has passed public notice and formally entered the innovative medical device special review program of the National Medical Products Administration's Center for Medical Device Evaluation (CMDE), commonly known as the green channel. The company describes it as the first subdural implantable flexible BCI product in China to enter the program. The system began a GCP registration clinical trial at Huashan Hospital, Fudan University on July 7, 2026, run as a multicentre study across 15 Class III hospitals nationwide, with trial data intended to support a Class III medical device registration application with the NMPA. The system remains in the review and clinical-trial stage and has not yet been approved for market; the registration timeline reflects company statements and remains subject to regulatory notice.

The State Council's National Health 15th Five-Year Plan (2026–2030) explicitly lists brain-computer interface (BCI) as a priority direction for basic research in the health sector, positioning it as a key technological breakthrough for major national science and technology projects in medical devices and biomedicine.

NeuroXess announced the launch of a GCP registration clinical trial at Huashan Hospital, Fudan University, for its implantable BCI system for hand motor function compensation. The trial aims to evaluate safety and efficacy for upper limb function compensation in people with tetraplegia caused by cervical spinal cord injury. According to the company, Professor Mao Ying's team serves as the principal investigator team, and the multicenter study involves 15 Grade III Class A hospitals. Data will support a Class III medical device registration application to the National Medical Products Administration. The system uses flexible electrodes on the cortical surface beneath the dura, with battery, wireless transmission and charging units under the skin of the chest. The announcement concerns trial initiation, not regulatory approval or demonstrated efficacy.

Paradromics has named William J. Marks chief clinical officer; he brings nearly three decades of experience in clinical neuroscience and implantable devices. The appointment comes as the company advances Connect-One, an early feasibility study of its Connexus BCI system, which is intended to restore communication for people who have lost it to spinal cord injury, stroke or ALS.

French medtech company BIOSerenity has built an EEG foundation model, BIOSerenity-E1, pre-trained self-supervised on more than 4,000 hours of recordings, and reports strong results on four clinical tasks: normal/abnormal classification, Alzheimer's disease detection, pediatric sleep staging and seizure detection. The normal/abnormal algorithm is already built into a CE-marked medical device, and the seizure-detection algorithm is in clinical evaluation. The work will be shown as a poster at the 8th Journées de Neurophysiologie Clinique in Grenoble, France.